ZA202206666B - Crystal form for treating liver disease and use thereof - Google Patents
Crystal form for treating liver disease and use thereofInfo
- Publication number
- ZA202206666B ZA202206666B ZA2022/06666A ZA202206666A ZA202206666B ZA 202206666 B ZA202206666 B ZA 202206666B ZA 2022/06666 A ZA2022/06666 A ZA 2022/06666A ZA 202206666 A ZA202206666 A ZA 202206666A ZA 202206666 B ZA202206666 B ZA 202206666B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystal form
- liver disease
- treating liver
- treating
- disease
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20008—Constructional details of analysers, e.g. characterised by X-ray source, detector or optical system; Accessories therefor; Preparing specimens therefor
- G01N23/2005—Preparation of powder samples therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/207—Diffractometry using detectors, e.g. using a probe in a central position and one or more displaceable detectors in circumferential positions
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010376938.9A CN112028940B (en) | 2020-05-07 | 2020-05-07 | Tenofovir phosphate crystal form and preparation and application thereof |
CN202010376833.3A CN112010905B (en) | 2020-05-07 | 2020-05-07 | Paradifovir mesylate crystal form and application thereof |
CN202010391424.0A CN112047990B (en) | 2020-05-11 | 2020-05-11 | Cytarabine prodrug MB07133 crystal form and application thereof |
PCT/CN2020/130060 WO2021223398A1 (en) | 2020-05-07 | 2020-11-19 | Crystal form for treating liver disease and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA202206666B true ZA202206666B (en) | 2023-09-27 |
Family
ID=78467750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2022/06666A ZA202206666B (en) | 2020-05-07 | 2022-06-15 | Crystal form for treating liver disease and use thereof |
Country Status (2)
Country | Link |
---|---|
WO (1) | WO2021223398A1 (en) |
ZA (1) | ZA202206666B (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100439387C (en) * | 2002-10-31 | 2008-12-03 | 美达贝斯制药有限公司 | Novel cytosine monophosphate medicine precursor |
RU2006138907A (en) * | 2004-06-08 | 2008-07-20 | Метабазис Терапеутикс | SYNTHESIS OF COMPLEX CYCLIC ETHERS USING LEWIS ACID |
CN101475594B (en) * | 2009-02-06 | 2012-05-30 | 廖国超 | Liver targeted antivirus precursor medicament annular phosphoester and use thereof |
AU2013257951A1 (en) * | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
CN102827206B (en) * | 2012-09-17 | 2015-06-17 | 西安新通药物研究有限公司 | Pradefovir crystal |
CN103333209B (en) * | 2013-07-05 | 2015-09-30 | 西安新通药物研究有限公司 | The new crystal of tynofovir prodrug (HTS) |
CN104710477A (en) * | 2013-12-16 | 2015-06-17 | 安徽贝克联合制药有限公司 | Tenofovir cyclic phosphonate compound and pharmaceutically acceptable salt thereof, and preparation methods and applications thereof |
KR20230070330A (en) * | 2014-07-10 | 2023-05-22 | 레플리코르 인코포레이티드 | Methods for the treatment of hepatitis b and hepatitis d virus infections |
CN107540710B (en) * | 2016-06-24 | 2020-10-16 | 浙江柏拉阿图医药科技有限公司 | Liver delivery antiviral prodrug nucleoside cyclic phosphate ester compound and application thereof |
-
2020
- 2020-11-19 WO PCT/CN2020/130060 patent/WO2021223398A1/en active Application Filing
-
2022
- 2022-06-15 ZA ZA2022/06666A patent/ZA202206666B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021223398A1 (en) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279688A (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
IL288061A (en) | Compounds and methods for the treatment of covid-19 | |
EP4010080C0 (en) | Heterocyclic compounds for use in the treatment of cancer | |
SG11202007226UA (en) | Methods and compositions for treating sleep apnea | |
IL283938A (en) | Compounds and their use for the treatment of α1-antitrypsin deficiency | |
IL280475A (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
EP3858353A4 (en) | Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof | |
IL285989A (en) | Method for treating fatty liver disease and/or steatohepatitis | |
IL289167A (en) | 2h-indazole derivatives and their use in the treatment of disease | |
IL285197A (en) | Methods and compositions for treating sleep apnea | |
IL276713A (en) | Variant cd3-binding domains and their use in combination therapies for the treatment of disease | |
ZA202100703B (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
IL292221A (en) | Compositions and methods for treating liver disease | |
DK3860990T3 (en) | Inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of cancer | |
IL282251A (en) | Compositions and methods for treatment of liver disease | |
IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
IL289309A (en) | Methods and materials for treating huntington’s disease | |
DK3937948T3 (en) | Phytoecdysones and derivatives thereof for use in the treatment of neuromuscular diseases | |
ZA202206666B (en) | Crystal form for treating liver disease and use thereof | |
IL274007A (en) | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same | |
GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
PL3810128T3 (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
ZA202107235B (en) | Compositions and methods for treating ocular disease |